checkAd
    Startseite > Aktien > Sight Sciences > Nachrichten
    Sight Sciences Aktie
    6,9100
     
    USD
    -3,36 %
    -0,2400 USD
    Letzter Kurs 22:30:00 Nasdaq
    6,8900
     
    USD
    100 STK
    Geldkurs 22:02:00
    6,9200
     
    USD
    400 STK
    Briefkurs 22:02:00
    ISIN: US82657M1053 · WKN: A3CU4L · SYM: SGHT · USA

    Neueste Nachrichten

    Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
    28.05.24 · globenewswire · Sight Sciences
    Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI Across Mild, Moderate, and Advanced Glaucoma
    28.05.24 · globenewswire · Sight Sciences
    Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
    07.05.24 · globenewswire · Sight Sciences
    Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
    02.05.24 · globenewswire · Sight Sciences
    Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
    29.04.24 · globenewswire · Sight Sciences
    Sight Sciences to Report First Quarter Financial Results on May 2, 2024
    18.04.24 · globenewswire · Sight Sciences
    Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI Surgical System-Technologie sowohl bei der Sen
    12.04.24 · globenewswire · Sight Sciences
    Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Y
    10.04.24 · globenewswire · Sight Sciences
    Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
    02.04.24 · globenewswire · Sight Sciences
    Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
    26.03.24 · globenewswire · Sight Sciences
    Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
    07.03.24 · globenewswire · Sight Sciences
    Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
    22.02.24 · globenewswire · Sight Sciences